Evidence map›Paper›PMID 35496791›Full record

ArticleSTAR protocols2022

Synthesis of

Sahil Sharma, Teja Kalidindi, Suhasini Joshi, Chander S Digwal, Palak Panchal, Eva Burnazi, Sang Gyu Lee, Nagavarakishore Pillarsetty, Gabriela Chiosis

Abstract read
In one paragraph

Article in STAR protocols, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Sahil SharmaProgram in Chemical Biology, Sloan Kettering Institute, New York, NY 10065, USA.
Teja KalidindiDepartment of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Suhasini JoshiProgram in Chemical Biology, Sloan Kettering Institute, New York, NY 10065, USA.
Chander S DigwalProgram in Chemical Biology, Sloan Kettering Institute, New York, NY 10065, USA.
Palak PanchalProgram in Chemical Biology, Sloan Kettering Institute, New York, NY 10065, USA.
Eva BurnaziDepartment of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Sang Gyu LeeDepartment of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Nagavarakishore PillarsettyDepartment of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Gabriela ChiosisProgram in Chemical Biology, Sloan Kettering Institute, New York, NY 10065, USA.

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4M
Translating Stress Response Targeted Therapy for B-Cell LymphomasP50CA192937 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI DALLA-FAVERA, RICCARDO, ZELENETZ, ANDREW D. · 2016 to 2020
$10.9M
Project 3: Structural Basis for grp94 Drug Development and Chaperone FunctionP01CA186866 · NCI · OHIO STATE UNIVERSITY · PI GEWIRTH, DANIEL T · 2015 to 2019
$6.7M
Impact of sex differences on the trajectory of interactome dysfunctions across the AD spectrumR01AG074004 · NIA · SLOAN-KETTERING INST CAN RESEARCH · PI CHIOSIS, GABRIELA, GINSBERG, STEPHEN D · 2021 to 2025
$6.0M
Chaperome networks in Alzheimer's diseaseR01AG067598 · NIA · SLOAN-KETTERING INST CAN RESEARCH · PI ARANCIO, OTTAVIO, CHIOSIS, GABRIELA · 2021 to 2025
$5.9M
[18F]-PU-AD epichaperome PET imaging probeRF1AG071805 · NIA · SLOAN-KETTERING INST CAN RESEARCH · PI CHIOSIS, GABRIELA, DUNPHY, MARK P. · 2022 to 2025
$4.8M
Memorial Sloan Kettering Small Animal Imaging ResearchR24CA083084 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI KOUTCHER, JASON ARTHUR · 1999 to 2006
$4.4M
Small molecule Hsp90 inhibitors in AD treatmentU01AG032969 · NIA · SLOAN-KETTERING INST CAN RESEARCH · PI CHIOSIS, GABRIELA · 2010 to 2014
$3.5M
Biomarkers for predicting response to Hsp90 therapyR01CA172546 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI CHIOSIS, GABRIELA, DUNPHY, MARK P. · 2013 to 2017
$2.9M
Targeting the heat shock response for the therapy of DLBCLR01CA155226 · NCI · WEILL MEDICAL COLL OF CORNELL UNIV · PI CHIOSIS, GABRIELA, MELNICK, ARI M. · 2011 to 2015
$2.5M
A chemical chaperomics platform for ADR56AG061869 · NIA · SLOAN-KETTERING INST CAN RESEARCH · PI CHIOSIS, GABRIELA · 2018 to 2019
$1.8M
Selective interactome vulnerability across the Alzheimer’s disease spectrumR56AG072599 · NIA · SLOAN-KETTERING INST CAN RESEARCH · PI CHIOSIS, GABRIELA, GINSBERG, STEPHEN D · 2021 to 2021
$1.2M
NCI NIH HHS P01 CA186866NCI NIH HHS P30 CA008748NCI NIH HHS P50 CA192937NCI NIH HHS R01 CA155226NCI NIH HHS R01 CA172546NCI NIH HHS R24 CA083084NIA NIH HHS R01 AG067598NIA NIH HHS R01 AG074004NIA NIH HHS R56 AG061869NIA NIH HHS R56 AG072599NIA NIH HHS RF1 AG071805NIA NIH HHS U01 AG032969
6 · The paper itself

Abstract

Epichaperomes are disease-associated pathologic scaffolds composed of tightly bound chaperones and co-chaperones. They provide opportunities for precision medicine where aberrant protein-protein interaction networks, rather than a single protein, are detected and targeted. This protocol describes the synthesis and characterization of two

Indexed as

NeoplasmsProtein Interaction MapsAnimalsIodine RadioisotopesMiceTomography, X-Ray ComputedIodine-124Iodine RadioisotopesCancerCell cultureChemistryModel OrganismsMolecular/Chemical Probes

Identifiers

PMID35496791
PMCPMC9046997

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.